Medicare would cover custom breast prostheses after mastectomy

Summary#

H.R. 10921 would amend Title XVIII of the Social Security Act to provide coverage for custom-fabricated breast prostheses after a mastectomy. Its stated goal, as reflected in the title, is to provide that coverage; the bill text was not supplied, so the details cannot be confirmed. The bill has been referred to House committees and is not law.

  • The proposed change concerns coverage for custom-fabricated breast prostheses following a mastectomy.
  • The supplied material does not identify who would qualify, what would be covered, or how coverage would work.
  • The Social Security Act being amended was not supplied, so current coverage and how the bill would change it could not be verified.

What it means for you#

  • People seeking a breast prosthesis after mastectomy: The title describes a proposed coverage change, but does not say who would qualify, what costs would be covered, or how to obtain coverage.
  • Other patients and the public: The supplied material does not describe changes to other coverage, services, rights, or requirements.

Money#

No publicly available information.

  • The supplied material has no cost estimate or details on spending, payment rates, or patient costs.

What is unclear#

  • What “custom fabricated” means for coverage, and whether the bill defines it.
  • Who would qualify and what documentation or limits would apply.
  • How coverage decisions, payment, appeals, and oversight would work.
  • How the proposal would interact with existing coverage; the current law text was not supplied.
  • The bill text and any funding, rules, or start date were not supplied. Passage is uncertain.

Case for#

  • A possible argument for the bill is that expressly providing coverage for custom-fabricated prostheses could help eligible people obtain them after a mastectomy.
  • The supplied material does not explain the problem the bill is meant to solve or how the proposed coverage would address it.

Case against#

  • One concern is that the bill’s title does not reveal eligibility limits, covered costs, or payment rules, making its practical effect hard to assess.
  • The cost to the public and any effect on patients’ out-of-pocket costs are unknown from the supplied material.